Literature DB >> 1423022

Central arginine vasopressin and endogenous antipyresis.

Q J Pittman1, M F Wilkinson.   

Abstract

Arginine vasopressin (AVP) is a centrally synthesized nonapeptide that exerts classical endocrine effects as well as a host of centrally mediated actions. A strong case can be argued in support of a neurotransmitter-neuromodulator role for AVP. Acting within the central nervous system (CNS), AVP has been demonstrated to be involved in the modulation of febrile body temperature. Because AVP acts to reduce pyrogen-induced fevers, but not normal body temperature, its actions are deemed to be antipyretic. However, to demonstrate an endogenous antipyretic function, AVP must be shown to be active during conditions where fever is naturally suppressed. This review will focus on five such conditions where the absence of pyrogen-induced fever can be linked to the endogenous activity of AVP within the brain. In the neonatal rat pup, the use of specific antagonists to the AVP receptor has revealed a role for CNS AVP in the absence of fever following peripheral injections of bacterial endotoxin. These results may help to explain a similar lack of fever in other newborn species. In parturient animals a reduced or absent febrile response has been linked to the increased presence of AVP within the septal area of the brain. The combined use of AVP receptor antagonism as well as immunohistochemistry has shown enhanced AVP activity within the ventral septal area of the rat and guinea pig brain during tolerance to intravenous pyrogens. These results suggest that the mechanism of fever suppression following repeated systemic injections of bacterial pyrogen includes centrally acting AVP.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1423022     DOI: 10.1139/y92-104

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  8 in total

Review 1.  Central and peripheral neuroimmune responses: hyporesponsiveness during pregnancy.

Authors:  Sarah J Spencer; Abdeslam Mouihate; Michael A Galic; Quentin J Pittman
Journal:  J Physiol       Date:  2007-10-18       Impact factor: 5.182

2.  Conformation and dynamics of 8-Arg-vasopressin in solution.

Authors:  Elke Haensele; Lee Banting; David C Whitley; Timothy Clark
Journal:  J Mol Model       Date:  2014-11-06       Impact factor: 1.810

3.  Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats.

Authors:  P Bardoux; H Martin; M Ahloulay; F Schmitt; N Bouby; M M Trinh-Trang-Tan; L Bankir
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

Review 4.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

5.  Alteration of the physiological responses to indomethacin by endotoxin tolerance in the rat: a possible role for central vasopressin.

Authors:  M F Wilkinson; Q J Pittman
Journal:  J Physiol       Date:  1994-09-15       Impact factor: 5.182

6.  Characterization of the effects of the vasopressin V2 receptor on sweating, fluid balance, and performance during exercise.

Authors:  Tamara Hew-Butler; Jed Hummel; Brian C Rider; Joseph G Verbalis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-06-18       Impact factor: 3.619

7.  The Modulatory Effect of Ischemia and Reperfusion on Arginine Vasopressin-Induced Arterial Reactions.

Authors:  Katarzyna Szadujkis-Szadurska; Bartosz Malinowski; Małgorzata Piotrowska; Grzegorz Grześk; Michał Wiciński; Marta Gajdus
Journal:  Biomed Res Int       Date:  2016-08-03       Impact factor: 3.411

Review 8.  New Insights into the Role of Glutathione in the Mechanism of Fever.

Authors:  Sylwia Wrotek; Justyna Sobocińska; Henryk M Kozłowski; Małgorzata Pawlikowska; Tomasz Jędrzejewski; Artur Dzialuk
Journal:  Int J Mol Sci       Date:  2020-02-19       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.